Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Pravastatin
Drug ID BADD_D01824
Description Pravastatin is the 6-alpha-hydroxy acid form of [mevastatin].[T303] Pravastatin was firstly approved in 1991 becoming the second available statin in the United States. It was the first statin administered as the active form and not as a prodrug.[T274] This drug was developed by Sankyo Co. Ltd.; however, the first approved pravastatin product was developed by Bristol Myers Squibb and FDA approved in 1991.[L6142] Pravastatin is made through a fermentation process in which [mevastatin] is first obtained. The manufacturing process is followed by the hydrolysis of the lactone group and the biological hydroxylation with _Streptomyces carbophilus_ to introduce the allylic 6-alcohol group.[T239]
Indications and Usage For the treatment of hypercholesterolemia and to reduce the risk of cardiovascular disease.
Marketing Status Prescription; Discontinued
ATC Code C10AA03
DrugBank ID DB00175
KEGG ID D08410
MeSH ID D017035
PubChem ID 54687
TTD Drug ID D02RQU
NDC Product Code Not Available
Synonyms Pravastatin | Eptastatin | Vasten | CS-514 | CS 514 | CS514 | Lin-Pravastatin | Lin Pravastatin | Lipemol | Liplat | Nu-Pravastatin | Nu Pravastatin | Prareduct | Mevalotin | Pravachol | Elisor | Selektine | Lipostat | Pravacol | Pravasin | Pravastatin Monosodium Salt, (6 beta)-Isomer | Pravastatin Sodium | Pravastatin Sodium Salt | Sodium Salt, Pravastatin | Pravastatin tert-Octylamine Salt | Pravastatin tert Octylamine Salt | Pravastatin, (6 beta)-Isomer | RMS-431 | RMS 431 | RMS431 | SQ-31000 | SQ 31000 | SQ31000 | SQ-31,000 | SQ 31,000 | SQ31,000 | Apo-Pravastatin | Apo Pravastatin | Bristacol
Chemical Information
Molecular Formula C23H36O7
CAS Registry Number 81093-37-0
SMILES CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC(CC(CC(=O)O)O)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Acute myocardial infarctionStromelysin-1P08254T8670210190398; 12485468; 16323393; 9420339
Angina pectorisStromelysin-1P08254T8670210190398; 12485468; 16323393; 9420339
AngioplastyStromelysin-1P08254T8670210190398; 12485468; 16323393; 9420339
ArteriosclerosisLiver carboxylesterase 1P23141T763699420339; 14660992; 14998629; 14984434
Cerebrovascular accidentStromelysin-1P08254T8670210190398; 12485468; 16323393; 9420339
DeathStromelysin-1P08254T8670210190398; 12485468; 16323393; 9420339
Myocardial ischaemiaApolipoprotein EP02649T2168910736278; 7605354
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Coronary artery disease24.04.04.006; 02.02.01.0010.000072%Not Available
Cough22.02.03.001--
Deafness04.02.01.001--Not Available
Death08.04.01.001--
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Dermatomyositis23.03.02.001; 15.05.01.002; 10.04.02.001--Not Available
Diarrhoea07.02.01.001--
Diplopia17.17.01.005; 06.02.06.002--Not Available
Discomfort08.01.08.003--Not Available
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Drug hypersensitivity10.01.01.0010.000941%Not Available
Drug interaction08.06.03.001--Not Available
Dry skin23.03.03.001--
Dysgeusia17.02.07.003; 07.14.03.001--
Dyspepsia07.01.02.0010.000109%
Dyspnoea22.02.01.004; 02.01.03.002--
Dysuria20.02.02.002--
Endophthalmitis11.01.06.003; 06.04.05.009--
Eosinophilia01.02.04.0010.000109%
Epistaxis24.07.01.005; 22.04.03.0010.000109%
Erythema multiforme10.01.03.015; 23.03.01.003--
Facial paralysis17.04.03.008--Not Available
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014--Not Available
Flatulence07.01.04.002--
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
Gait disturbance17.02.05.016; 08.01.02.0020.000109%
Gamma-glutamyltransferase increased13.03.01.011--
Gastrointestinal disorder07.11.01.0010.000072%Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 7 Pages